Related Experiment Video
Updated: Jun 17, 2026
Uracil-DNA Glycosylase Assay by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry Analysis
Published on: April 22, 2022
Detection of adriamycin-DNA adducts by accelerator mass spectrometry
Kate Coldwell1, Suzanne M Cutts, Ted J Ognibene
1Department of Biochemistry, La Trobe University, Bundoora, VIC, Australia.
Abstract:
There have been many attempts in the past to determine whether significant levels of Adriamycin-DNA adducts form in cells and contribute to the anticancer activity of this agent. Supraclincal drug levels have been required to study drug-DNA adducts because of the lack of sensitivity associated with many of the techniques employed, including liquid scintillation counting of radiolabeled drug. The use of accelerator mass spectrometry (AMS) has provided the first direct evidence of Adriamycin-DNA adduct formation in cells at clinically relevant Adriamycin concentrations. The exceedingly sensitive nature of AMS has enabled over three orders of magnitude increased sensitivity of Adriamycin-DNA adduct detection (compared to liquid scintillation counting) and has revealed adduct formation within an hour of drug treatment. The rigorous protocol required for this approach, together with many notes on the precautions and procedures required in order to ensure that absolute levels of Adriamycin-DNA adducts can be determined with good reproducibility, is outlined in this chapter.
Insights
Accelerator Mass Spectrometry (AMS) detects Adriamycin-DNA adducts at clinically relevant levels, providing direct evidence of their formation in cells. This sensitive method reveals adducts within an hour of treatment, advancing cancer drug research.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- Adriamycin is an anticancer drug whose DNA adducts' role in its efficacy is debated.
- Previous detection methods lacked sensitivity, requiring supra-clinical drug levels.
Purpose of the Study:
- To provide direct evidence of Adriamycin-DNA adduct formation at clinically relevant concentrations.
- To establish a sensitive and reproducible method for quantifying Adriamycin-DNA adducts.
Main Methods:
- Utilized Accelerator Mass Spectrometry (AMS) for highly sensitive detection of Adriamycin-DNA adducts.
- Compared AMS sensitivity to traditional liquid scintillation counting.
Main Results:
- AMS provided the first direct evidence of Adriamycin-DNA adduct formation at clinically relevant concentrations.
- AMS demonstrated over three orders of magnitude greater sensitivity than liquid scintillation counting.
- Adduct formation was detected within one hour of Adriamycin treatment.
Conclusions:
- AMS is a powerful tool for detecting Adriamycin-DNA adducts at physiologically relevant levels.
- This finding supports the contribution of Adriamycin-DNA adducts to the drug's anticancer activity.
- The described protocol ensures reproducible and accurate quantification of these adducts.
More Related Videos
10:12Quantitative Detection of DNA-Protein Crosslinks and Their Post-Translational Modifications
Published on: April 21, 2023
12:15Quantification of three DNA Lesions by Mass Spectrometry and Assessment of Their Levels in Tissues of Mice Exposed to Ambient Fine Particulate Matter
Published on: May 29, 2019